Andere talen Bristol-Myers Squibb Company

Aandelen

BMY

US1101221083

Beurs gesloten - Nyse Andere beurzen 22:00:02 18-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
48,3 ^USD	+0,96%		-1,67%	-5,87%

18/04	BRISTOL-MYERS SQUIBB COMPANY : Wells Fargo Securities is Neutraal gestemd over aandeel	ZM
15/04	BRISTOL-MYERS SQUIBB COMPANY : Wolfe Research herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

US FDA mandates label updates on CAR-T cancer therapies	00:33
Actinium Pharmaceuticals (ATNM) Garners Attention with Clinical Successes and Strategic Market Moves Amid Growing Radiopharma Interest	17/04
TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors	17/04
Asher Biotherapeutics, Inc. announced that it has received $55 million in funding from a group of investors	16/04
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Bristol-Myers Squibb Company - BMY	12/04
TORL BioTherapeutics LLC announces tranche update	10/04
Bristol Myers : résultats d'un traitement pour le cancer	09/04
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)	08/04
Bristol Myers Squibb Announces KRAZATI in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer	08/04
Global markets live: Boeing, Shell, AstraZeneca, Tesla, Meta...	08/04
EE.UU. - Valores a seguir en Wall Street (actualizado)	08/04
U.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma after Two Prior Lines of Therapy	08/04
Bristol Myers : de nouvelles données sur la schizophrénie	08/04
Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society	06/04
Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society	06/04
Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies	06/04
Bristol-Myers Squibb, 2seventy Bio Say FDA Approves Expansion of Myeloma Treatment's Indication	05/04
Bristol Myers, 2seventy Get FDA OK for Earlier Abecma Use in Multiple Myeloma	05/04
Bristol Myers : la FDA valide Abecma dans le myélome multiple	05/04
US FDA allows expanded use of Bristol Myers' cell therapy for blood cancer	05/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Headlines

Bristol-Myers CEO zegt dat het bedrijf in overgang is

09 januari 2024 om 19:06 uur